Neovasc Inc. (NVCN) Scheduled to Post Quarterly Earnings on Tuesday
Neovasc Inc. (NASDAQ:NVCN) (TSE:NVC) is scheduled to announce its earnings results after the market closes on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter.
Neovasc (NASDAQ:NVCN) (TSE:NVC) last posted its earnings results on Thursday, August 10th. The medical equipment provider reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.02). The company had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.40 million. Neovasc had a negative net margin of 68.34% and a negative return on equity of 58.08%. On average, analysts expect Neovasc to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Neovasc Inc. (NASDAQ NVCN) opened at $1.05 on Monday. The company has a market capitalization of $82.86, a P/E ratio of 5.00 and a beta of 0.27. Neovasc Inc. has a fifty-two week low of $0.47 and a fifty-two week high of $3.34.
Separately, Zacks Investment Research raised Neovasc from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Wednesday, October 11th.
COPYRIGHT VIOLATION NOTICE: “Neovasc Inc. (NVCN) Scheduled to Post Quarterly Earnings on Tuesday” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/13/neovasc-inc-nvcn-scheduled-to-post-quarterly-earnings-on-tuesday.html.
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.